STOCK TITAN

Option Care Health Reports Financial Results for Fourth Quarter and Full Year 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags

Option Care Health (NASDAQ: OPCH) has released its Q4 and full-year 2024 financial results, showing strong revenue growth but mixed profitability metrics. Q4 2024 highlights include net revenue of $1,346.4M (up 19.7% YoY), net income of $60.1M, and adjusted EBITDA of $121.6M (up 8.9% YoY).

Full-year 2024 performance showed net revenue of $4,998.2M (up 16.2% YoY), though net income decreased to $211.8M from $267.1M in 2023. The company's gross profit margin declined to 20.3% from 22.8% in 2023.

For 2025 guidance, Option Care Health projects net revenue of $5.3B-$5.5B, adjusted EBITDA of $450M-$470M, and adjusted EPS of $1.59-$1.69. The company repurchased approximately $90.0M of stock in Q4 2024.

Option Care Health (NASDAQ: OPCH) ha pubblicato i risultati finanziari del Q4 e dell'intero anno 2024, mostrando una forte crescita dei ricavi ma metriche di redditività miste. I punti salienti del Q4 2024 includono ricavi netti di $1.346,4M (in aumento del 19,7% rispetto all'anno precedente), un reddito netto di $60,1M e un EBITDA rettificato di $121,6M (in aumento dell'8,9% rispetto all'anno precedente).

Le performance dell'anno intero 2024 hanno mostrato ricavi netti di $4.998,2M (in aumento del 16,2% rispetto all'anno precedente), sebbene il reddito netto sia diminuito a $211,8M rispetto ai $267,1M del 2023. Il margine di profitto lordo dell'azienda è diminuito al 20,3% rispetto al 22,8% del 2023.

Per la guida 2025, Option Care Health prevede ricavi netti tra $5,3B e $5,5B, un EBITDA rettificato tra $450M e $470M, e un EPS rettificato tra $1,59 e $1,69. L'azienda ha riacquistato circa $90,0M di azioni nel Q4 2024.

Option Care Health (NASDAQ: OPCH) ha publicado sus resultados financieros del Q4 y del año completo 2024, mostrando un fuerte crecimiento en los ingresos, pero métricas de rentabilidad mixtas. Los aspectos destacados del Q4 2024 incluyen ingresos netos de $1,346.4M (un aumento del 19.7% interanual), un ingreso neto de $60.1M y un EBITDA ajustado de $121.6M (un aumento del 8.9% interanual).

El rendimiento del año completo 2024 mostró ingresos netos de $4,998.2M (un aumento del 16.2% interanual), aunque el ingreso neto disminuyó a $211.8M desde $267.1M en 2023. El margen de beneficio bruto de la empresa disminuyó al 20.3% desde el 22.8% en 2023.

Para la guía 2025, Option Care Health proyecta ingresos netos de entre $5.3B y $5.5B, un EBITDA ajustado de entre $450M y $470M, y un EPS ajustado de entre $1.59 y $1.69. La empresa recompró aproximadamente $90.0M en acciones en el Q4 2024.

Option Care Health (NASDAQ: OPCH)는 2024년 4분기 및 연간 재무 결과를 발표하였으며, 강력한 매출 성장과 혼합된 수익성 지표를 보였습니다. 2024년 4분기의 주요 내용으로는 순매출 $1,346.4M(전년 대비 19.7% 증가), 순이익 $60.1M, 조정 EBITDA $121.6M(전년 대비 8.9% 증가)입니다.

2024년 전체 성과는 순매출 $4,998.2M(전년 대비 16.2% 증가)을 기록했으나, 순이익은 2023년의 $267.1M에서 $211.8M으로 감소했습니다. 회사의 총 이익률은 2023년 22.8%에서 20.3%로 감소했습니다.

2025년 가이던스에 따르면, Option Care Health는 순매출을 $5.3B에서 $5.5B로, 조정 EBITDA를 $450M에서 $470M로, 조정 EPS를 $1.59에서 $1.69로 예상하고 있습니다. 회사는 2024년 4분기에 약 $90.0M의 주식을 재매입했습니다.

Option Care Health (NASDAQ: OPCH) a publié ses résultats financiers du 4ème trimestre et de l'année complète 2024, montrant une forte croissance des revenus mais des indicateurs de rentabilité mitigés. Les points saillants du 4ème trimestre 2024 incluent un revenu net de 1 346,4 M$ (en hausse de 19,7 % par rapport à l'année précédente), un revenu net de 60,1 M$ et un EBITDA ajusté de 121,6 M$ (en hausse de 8,9 % par rapport à l'année précédente).

La performance de l'année complète 2024 a montré un revenu net de 4 998,2 M$ (en hausse de 16,2 % par rapport à l'année précédente), bien que le revenu net ait diminué à 211,8 M$ contre 267,1 M$ en 2023. La marge brute de l'entreprise a diminué à 20,3 % contre 22,8 % en 2023.

Pour la prévision 2025, Option Care Health prévoit un revenu net de 5,3 à 5,5 milliards de dollars, un EBITDA ajusté de 450 à 470 millions de dollars et un EPS ajusté de 1,59 à 1,69 $. L'entreprise a racheté environ 90,0 millions de dollars d'actions au 4ème trimestre 2024.

Option Care Health (NASDAQ: OPCH) hat seine finanziellen Ergebnisse für das 4. Quartal und das Gesamtjahr 2024 veröffentlicht, die ein starkes Umsatzwachstum, jedoch gemischte Rentabilitätskennzahlen zeigen. Zu den Highlights des 4. Quartals 2024 gehören ein Nettoumsatz von $1.346,4M (19,7% im Jahresvergleich gestiegen), ein Nettogewinn von $60,1M und ein bereinigtes EBITDA von $121,6M (8,9% im Jahresvergleich gestiegen).

Die Leistung des Gesamtjahres 2024 zeigte einen Nettoumsatz von $4.998,2M (16,2% im Jahresvergleich gestiegen), obwohl der Nettogewinn von $267,1M im Jahr 2023 auf $211,8M gesunken ist. Die Bruttogewinnmarge des Unternehmens fiel von 22,8% im Jahr 2023 auf 20,3%.

Für die Prognose 2025 rechnet Option Care Health mit einem Nettoumsatz von $5,3B bis $5,5B, einem bereinigten EBITDA von $450M bis $470M und einem bereinigten EPS von $1,59 bis $1,69. Das Unternehmen hat im 4. Quartal 2024 etwa $90,0M an Aktien zurückgekauft.

Positive
  • Revenue growth of 19.7% in Q4 2024
  • Q4 adjusted EPS up 15.8% to $0.44
  • Full-year revenue up 16.2% to $4.99B
  • $90M stock repurchase in Q4 2024
  • Projected revenue growth to $5.3B-$5.5B in 2025
Negative
  • Gross profit margin declined from 22.8% to 20.3% in 2024
  • Full-year net income decreased from $267.1M to $211.8M
  • Cash flow from operations down 12.9% to $323.4M
  • Diluted EPS declined 16.9% to $1.23 in 2024

Insights

Option Care Health delivered strong revenue growth in Q4 2024, with a 19.7% increase to $1.35 billion, capping a full year where revenue grew 16.2% to $5.0 billion. However, this top-line expansion comes with notable margin compression, as gross margins declined from 22.0% to 19.9% in Q4 and from 22.8% to 20.3% for the full year.

The divergence between GAAP and adjusted metrics reveals important dynamics. While adjusted EPS increased 15.8% to $0.44 in Q4 and 10.5% to $1.58 for the year, GAAP EPS declined 16.9% for the full year to $1.23. This significant gap primarily stems from amortization expenses and integration costs as the company scales operations.

The declining cash flow trend is concerning - Q4 operating cash flow dropped 29.1% to $36.1 million, while full-year cash flow decreased 12.9% to $323.4 million. This cash flow compression coupled with $90 million in Q4 share repurchases signals management's confidence but warrants monitoring of the company's capital allocation strategy.

The 2025 guidance projects continued but decelerating growth, with revenue of $5.3-5.5 billion (approximately 8% growth at midpoint) and adjusted EBITDA of $450-470 million (roughly 3.5% growth). The modest adjusted EPS growth forecast ($1.59-1.69 versus $1.58 in 2024) suggests ongoing margin challenges despite scale advantages.

As the home healthcare market continues expanding due to aging demographics and cost-containment pressures from insurers and government programs, Option Care Health's market leadership position remains valuable. However, investors should closely monitor gross margin trends, cash flow generation, and the company's ability to translate revenue growth into proportional earnings growth in coming quarters.

BANNOCKBURN, Ill., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2024.

Fourth Quarter 2024 Financial Highlights

  • Net revenue of $1,346.4 million, up 19.7% compared to $1,124.4 million in the fourth quarter of 2023
  • Gross profit of $268.4 million, or 19.9% of net revenue, up 8.6% compared to $247.1 million, or 22.0% of net revenue, in the fourth quarter of 2023
  • Net income of $60.1 million, compared to net income of $57.2 million, in the fourth quarter of 2023 and diluted earnings per share of $0.35, up 9.4% compared to diluted earnings per share of $0.32 in the fourth quarter of 2023
  • Adjusted net income of $75.5 million, compared to adjusted net income of $66.7 million in the fourth quarter of 2023 and adjusted diluted earnings per share of $0.44, up 15.8% compared to adjusted diluted earnings per share of $0.38 in the fourth quarter of 2023
  • Adjusted EBITDA of $121.6 million, up 8.9% compared to $111.6 million in the fourth quarter of 2023
  • Cash flow from operations of $36.1 million, down 29.1% compared to cash flow from operations of $51.0 million in the fourth quarter of 2023
  • Repurchased approximately $90.0 million of stock in the fourth quarter of 2024

Full Year 2024 Financial Highlights

  • Net revenue of $4,998.2 million, up 16.2% compared to $4,302.3 million in full year 2023
  • Gross profit of $1,013.0 million, or 20.3% of revenue, up 3.2% compared to $981.2 million, or 22.8% of revenue, in full year 2023
  • Net income of $211.8 million, compared to net income of $267.1 million in full year 2023 and diluted earnings per share of $1.23, down 16.9% compared to diluted earnings per share of $1.48, inclusive of the impact from non-operating income, in full year 2023
  • Adjusted net income of $272.8 million, compared to adjusted net income of $257.7 million in full year 2023 and adjusted diluted earnings per share of $1.58, up 10.5% compared to adjusted diluted earnings per share of $1.43 in full year 2023
  • Adjusted EBITDA of $443.8 million, up 4.4% compared to $425.2 million in full year 2023
  • Cash flow from operations of $323.4 million, down 12.9% compared to $371.3 million in full year 2023

John C. Rademacher, Chief Executive Officer, commented, “The Option Care Health team’s execution produced solid financial results in the fourth quarter and full year 2024, demonstrating resilience in a dynamic and challenging period, while continuing to place the patient at the center of everything that we do. I am excited about the road ahead and the opportunity to leverage our capabilities to provide more patients high quality, affordable care, in a setting in which they wish to receive it.”

Full Year 2025 Financial Guidance

For the full year 2025, Option Care Health expects to deliver the following financial results:

  • Net revenue of $5.3 billion to $5.5 billion
  • Adjusted diluted earnings per share of $1.59 to $1.69
  • Adjusted EBITDA of $450 million to $470 million
  • Cash flow from operations of at least $320 million
  • Effective tax rate of 25% - 27%
  • Net interest expense of approximately $55 million to $60 million

Conference Call

Option Care Health will host a conference call to discuss its financial results later today at 8:30 a.m. EST. The conference call can be accessed via a live audio webcast that will be available online at investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members, including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates. To learn more, please visit our website at optioncarehealth.com.

Investor Contact

Mike Shapiro
Chief Financial Officer
T: (312) 940-2538
mike.shapiro@optioncare.com

Forward-Looking Statements - Safe Harbor

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our services and offerings; pending and future litigation; potential liability for claims not covered by insurance; and loss of relationships with managed care organizations and other non-governmental third party payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our periodic reports as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted net income, Adjusted EBITDA and Adjusted earnings per share ("Adjusted EPS"), which are non-GAAP financial measures. These adjusted measures are not measurements of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, earnings per share, or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definitions of Adjusted net income, Adjusted EBITDA, and Adjusted EPS may not be comparable to similarly titled non-GAAP financial measures reported by other companies. As defined by the Company: (i) Adjusted net income represents net income before intangible asset amortization expense, stock-based compensation expense, and restructuring, acquisition, integration and other expenses, net of tax adjustments (ii) Adjusted EBITDA represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other expenses, and (iii) Adjusted earnings per share represents Adjusted net income divided by weighted average common shares outstanding, diluted. As part of restructuring, acquisition, integration and other expenses, the Company may incur significant charges such as the write down of certain long‑lived assets, temporary redundant expenses, professional fees, certain litigation expenses and reserves related to acquired businesses, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that these adjusted measures provide useful supplemental information regarding the performance of Option Care Health’s business operations and facilitate comparisons to the Company’s historical operating results. We have not reconciled Adjusted EBITDA or Adjusted diluted earnings per share guidance to net income as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. Full reconciliations of each adjusted measure to the most comparable GAAP financial measure are set forth below.

Schedule 1
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)(UNAUDITED)

 December 31,
  2024  2023
ASSETS   
CURRENT ASSETS:   
Cash and cash equivalents$412,565 $343,849
Accounts receivable, net 409,733  377,658
Inventories 388,131  274,004
Prepaid expenses and other current assets 112,198  98,744
Total current assets 1,322,627  1,094,255
    
NONCURRENT ASSETS:   
Property and equipment, net 127,367  120,630
Intangible assets, net 16,993  20,092
Referral sources, net 284,017  315,304
Goodwill 1,540,246  1,540,246
Other noncurrent assets 130,493  126,508
Total noncurrent assets 2,099,116  2,122,780
TOTAL ASSETS$3,421,743 $3,217,035
    
LIABILITIES AND STOCKHOLDERS’ EQUITY   
CURRENT LIABILITIES:   
Accounts payable$610,779 $426,513
Other current liabilities 169,367  191,796
Total current liabilities 780,146  618,309
    
NONCURRENT LIABILITIES:   
Long-term debt, net of discount, deferred financing costs and current portion 1,104,641  1,056,650
Other noncurrent liabilities 132,718  120,404
Total noncurrent liabilities 1,237,359  1,177,054
Total liabilities 2,017,505  1,795,363
    
STOCKHOLDERS' EQUITY 1,404,238  1,421,672
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$3,421,743 $3,217,035


Schedule 2
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)

 Three Months Ended
December 31,
 Year Ended
December 31,
  2024   2023   2024   2023 
NET REVENUE$1,346,418  $1,124,390  $4,998,202  $4,302,324 
COST OF REVENUE 1,078,039   877,267   3,985,209   3,321,101 
GROSS PROFIT 268,379   247,123   1,012,993   981,223 
        
OPERATING COSTS AND EXPENSES:       
Selling, general and administrative expenses 164,727   147,783   630,251   607,427 
Depreciation and amortization expense 16,615   14,784   60,909   59,201 
Total operating expenses 181,342   162,567   691,160   666,628 
OPERATING INCOME 87,037   84,556   321,833   314,595 
        
OTHER INCOME (EXPENSE):       
Interest expense, net (10,879)  (12,432)  (49,029)  (51,248)
Other, net 4,891   6,801   10,795   95,395 
Total other (expense) income (5,988)  (5,631)  (38,234)  44,147 
        
INCOME BEFORE INCOME TAXES 81,049   78,925   283,599   358,742 
INCOME TAX EXPENSE 20,916   21,748   71,776   91,652 
NET INCOME$60,133  $57,177  $211,823  $267,090 
        
Earnings per share, basic$0.36  $0.32  $1.23  $1.49 
Earnings per share, diluted$0.35  $0.32  $1.23  $1.48 
        
Weighted average common shares outstanding, basic 168,816   176,055   171,567   178,973 
Weighted average common shares outstanding, diluted 169,980   177,743   172,845   180,375 


Schedule 3
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)(UNAUDITED)

 Year Ended
December 31,
  2024   2023 
CASH FLOWS FROM OPERATING ACTIVITIES:   
Net income$211,823  $267,090 
Adjustments to reconcile net income to net cash provided by operations:   
Depreciation and amortization expense 63,498   62,200 
Deferred income taxes - net 12,656   12,766 
Other non-cash adjustments 55,661   50,684 
Changes in operating assets and liabilities:   
Accounts receivable, net (32,075)  224 
Inventories (114,127)  (51,000)
Accounts payable 183,395   47,703 
Other (57,439)  (18,372)
Net cash provided by operating activities 323,392   371,295 
    
CASH FLOWS FROM INVESTING ACTIVITIES:   
Acquisition of property and equipment (35,606)  (41,866)
Proceeds from sale of assets    3,743 
Business acquisitions, net of cash acquired    (12,494)
Other investing activities (864)  (5,889)
Net cash used in investing activities (36,470)  (56,506)
    
CASH FLOWS FROM FINANCING ACTIVITIES:   
Proceeds from issuance of debt 49,959    
Purchase of company stock and related excise taxes (252,726)  (250,261)
Other financing activities (15,439)  (14,865)
Net cash used in financing activities (218,206)  (265,126)
    
NET INCREASE IN CASH AND CASH EQUIVALENTS 68,716   49,663 
Cash and cash equivalents - beginning of the period 343,849   294,186 
CASH AND CASH EQUIVALENTS - END OF PERIOD$412,565  $343,849 


Schedule 4
OPTION CARE HEALTH, INC.
RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(IN THOUSANDS)(UNAUDITED)

 Three Months Ended
December 31,
 Year Ended
December 31,
  2024   2023   2024   2023 
Net income$60,133  $57,177  $211,823  $267,090 
Interest expense, net 10,879   12,432   49,029   51,248 
Income tax expense 20,916   21,748   71,776   91,652 
Depreciation and amortization expense 17,469   15,777   63,498   62,200 
EBITDA 109,397   107,134   396,126   472,190 
        
EBITDA adjustments       
Stock-based incentive compensation expense 8,523   7,571   36,143   30,479 
Loss on extinguishment of debt       377    
Restructuring, acquisition, integration and other (1) 3,639   (3,103)  11,143   (77,486)
Adjusted EBITDA$121,559  $111,602  $443,789  $425,183 
        
Net income$60,133  $57,177  $211,823  $267,090 
Intangible asset amortization expense 8,596   8,629   34,405   34,381 
Stock-based incentive compensation expense 8,523   7,571   36,143   30,479 
Restructuring, acquisition, integration and other (1) 3,639   (3,103)  11,143   (77,486)
Total pre-tax adjustments 20,758   13,097   81,691   (12,626)
Tax adjustments (2) (5,356)  (3,615)  (20,668)  3,220 
Adjusted net income$75,535  $66,659  $272,846  $257,684 
        
Earnings per share, diluted$0.35  $0.32  $1.23  $1.48 
Adjusted earnings per share, diluted$0.44  $0.38  $1.58  $1.43 
Weighted average common shares outstanding, diluted 169,980   177,743   172,845   180,375 

(1) Restructuring, acquisition, integration and other for the year ended December 31, 2023 includes the Amedisys merger termination fee, net of merger-related expenses

(2) Tax adjustments for the three months and year ended December 31, 2024 and 2023 includes the estimated income tax effect on non-GAAP adjustments based on the effective tax rate


FAQ

What was Option Care Health's (OPCH) revenue growth in Q4 2024?

OPCH's Q4 2024 revenue grew 19.7% year-over-year to $1,346.4 million from $1,124.4 million in Q4 2023.

How much did Option Care Health's (OPCH) gross profit margin decline in 2024?

OPCH's gross profit margin decreased from 22.8% in 2023 to 20.3% in 2024.

What is Option Care Health's (OPCH) revenue guidance for 2025?

OPCH expects net revenue between $5.3 billion to $5.5 billion for full-year 2025.

How much stock did Option Care Health (OPCH) repurchase in Q4 2024?

OPCH repurchased approximately $90.0 million of stock in Q4 2024.

What was Option Care Health's (OPCH) cash flow from operations in 2024?

OPCH generated $323.4 million in cash flow from operations in 2024, down 12.9% from $371.3 million in 2023.

Option Care Health Inc

NASDAQ:OPCH

OPCH Rankings

OPCH Latest News

OPCH Stock Data

5.49B
163.98M
0.55%
107.18%
2.52%
Medical Care Facilities
Services-home Health Care Services
Link
United States
BANNOCKBURN